RT Book, Section A1 Gaitonde, Shrawan G. A1 Ahmad, Syed A. A2 Morita, Shane Y. A2 Balch, Charles M. A2 Klimberg, V. Suzanne A2 Pawlik, Timothy M. A2 Posner, Mitchell C. A2 Tanabe, Kenneth K. SR Print(0) ID 1145764875 T1 Pancreatic Cancer: Principles of Pancreaticoduodenectomy and Distal Pancreatectomy T2 Textbook of Complex General Surgical Oncology YR 2018 FD 2018 PB McGraw-Hill Education PP New York, NY SN 9780071793315 LK accesssurgery.mhmedical.com/content.aspx?aid=1145764875 RD 2024/03/28 AB Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related deaths in the United States and the eighth worldwide. Despite advances in medical therapy, survival remains poor. The median survival for patients diagnosed with PDA is 4 to 6 months. However, for the 10% to 20% of patients who are operative candidates at the time of diagnosis, the 5-year overall survival approaches 25%, and the median survival is in the range of 20 to 22 months. The incidence of pancreatic cancer has slowly risen over the last decade, resulting in over 310,000 annual deaths worldwide.1 The aggressive nature of pancreatic cancer can be seen as each year the incidence nearly matches the death rate, and accounts for about 42,000 deaths annually in the United States alone.2 Given this aggressiveness and poor long-term outcomes, high variability exists in the surgical approach to patients with pancreatic cancer. Many aspects of surgery for pancreatic cancer have been evaluated including the appropriate workup and staging, need for laparoscopy, need for extended lymphadenectomies, and the use of vascular reconstruction to improve morbidity and survival. The following is a comprehensive review of the available data regarding the surgical management of patients with resectable pancreatic cancer.